JP2024533162A5 - - Google Patents

Info

Publication number
JP2024533162A5
JP2024533162A5 JP2024513937A JP2024513937A JP2024533162A5 JP 2024533162 A5 JP2024533162 A5 JP 2024533162A5 JP 2024513937 A JP2024513937 A JP 2024513937A JP 2024513937 A JP2024513937 A JP 2024513937A JP 2024533162 A5 JP2024533162 A5 JP 2024533162A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042448 external-priority patent/WO2023034564A2/en
Publication of JP2024533162A publication Critical patent/JP2024533162A/ja
Publication of JP2024533162A5 publication Critical patent/JP2024533162A5/ja
Pending legal-status Critical Current

Links

JP2024513937A 2021-09-02 2022-09-02 抗cd33抗体及びその使用 Pending JP2024533162A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240220P 2021-09-02 2021-09-02
US63/240,220 2021-09-02
PCT/US2022/042448 WO2023034564A2 (en) 2021-09-02 2022-09-02 Anti-cd33 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024533162A JP2024533162A (ja) 2024-09-12
JP2024533162A5 true JP2024533162A5 (cg-RX-API-DMAC7.html) 2025-09-09

Family

ID=85412855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513937A Pending JP2024533162A (ja) 2021-09-02 2022-09-02 抗cd33抗体及びその使用

Country Status (7)

Country Link
US (1) US20240262910A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396235A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533162A (cg-RX-API-DMAC7.html)
CN (1) CN118234750A (cg-RX-API-DMAC7.html)
AU (1) AU2022340645A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228414A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023034564A2 (cg-RX-API-DMAC7.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535823A (ja) * 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3307779A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
AU2018240556B2 (en) * 2017-03-24 2025-02-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same

Similar Documents

Publication Publication Date Title
JP2023516936A5 (cg-RX-API-DMAC7.html)
JP2018500014A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
TW201909926A (zh) B7h3抗體-藥物偶聯物及其醫藥用途
JP2023543031A5 (cg-RX-API-DMAC7.html)
JP2011501656A5 (cg-RX-API-DMAC7.html)
RU2009107895A (ru) Антигенсвязывающие молекулы, которые связывают рецептор эпидермального фактора роста (fgfr), кодирующие их векторы и их применение
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
JP2022527151A5 (cg-RX-API-DMAC7.html)
JP2010537671A5 (cg-RX-API-DMAC7.html)
BRPI0620632A2 (pt) composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits
JP2012521218A5 (cg-RX-API-DMAC7.html)
JP2019534705A5 (cg-RX-API-DMAC7.html)
JP2022547718A5 (cg-RX-API-DMAC7.html)
JP2024504390A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2026041756A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2019524640A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2024537323A5 (cg-RX-API-DMAC7.html)
JP2022512646A5 (cg-RX-API-DMAC7.html)
JP2024534892A5 (cg-RX-API-DMAC7.html)
JP2023537958A (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
WO2015105973A1 (en) ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF